GALT Stock Analysis: Buy, Sell, or Hold?
GALT - Galectin Therapeutics Inc.
$2.92
0.08 (3.00%)
▲
5d:
-6.57%
30d:
-29.93%
90d:
-42.5%
HOLD
LOW Confidence
Last Updated: January 30, 2026
Earnings: Mar 26, 2026
Get Alerted When GALT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
10 traders called GALT this week
93% bullish • 1 bearish
93% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GALT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: GALT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: GALT is currently trading at $2.92, which is considered oversold relative to its 30-day fair value range of $2.94 to $3.79.
Technical Outlook: Technically, GALT is in a downtrend. Immediate support is located at $2.76, while resistance sits at $3.56. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $11.00 (+288.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GALT is in a downtrend. Immediate support is located at $2.76, while resistance sits at $3.56. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $11.00 (+288.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.94 -
$3.79
Company Quality Score
44/100
(HOLD)
Options IV Signal
100th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
69.6%
Protect Your Profits
Holding GALT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 100th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.0%)
- BULLISH: Trading 288.7% below Wall St target ($11.00)
- CAUTION: Recommendation downgraded due to -6.6% 5-day decline
Fair Price Analysis
30-Day Fair Range
$2.94 -
$3.79
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$0.75
(25.6%)
Support & Resistance Levels
Support Level
$2.76
Resistance Level
$3.56
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-6.90
Wall Street Target
$11.00
(+288.7%)
Last updated: February 02, 2026 9:53 AM ET
Data refreshes hourly during market hours. Next update: 10:53 AM
Data refreshes hourly during market hours. Next update: 10:53 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GALT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Fund L.P. 10X
SELL
50000 shares
2025-10-22
Jack W Callicutt
SELL
8706 shares
2025-09-12
Joel Lewis
SELL
14000 shares
2025-09-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
Advanced GALT Option Strategies
Professional options setups generated by AI based on today's GALT price and gamma walls.
